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Abstract
Background: We retrospectively evaluated the efficacy and toxicity of gross tumor volume (GTV) mean-dose-optimized
and real-time motion-compensated robotic stereotactic body radiation therapy (SBRT) in the treatment of liver
metastases.
Methods: Between March 2011 and July 2015, 52 patients were treated with SBRT for a total of 91 liver
metastases (one to four metastases per patient) with a median GTV volume of 12 cc (min 1 cc, max 372 cc).
The optimization of mean GTV dose was prioritized during treatment planning at the potential cost of planning
target volume (PTV) coverage reduction while adhering to safe normal tissue constraints. The delivered median
GTV biological effective dose (BED10) was 142.1 Gy10 (range, 60.2 Gy10 –165.3 Gy10) and the prescribed PTV
BED10 ranged from 40.6 Gy10 to 112.5 Gy10 (median, 86.1 Gy10). We analyzed local control (LC), progression-free
interval (PFI), overall survival (OS), and toxicity.
Results: Median follow-up was 17 months (range, 2–49 months). The 2-year actuarial LC, PFI, and OS rates were
82.1, 17.7, and 45.0 %, and the median PFI and OS were 9 and 23 months, respectively. In univariate analysis
histology (p < 0.001), PTV prescription BED10 (HR 0.95, CI 0.91–0.98, p = 0.002) and GTV mean BED10 (HR 0.975, CI
0.954–0.996, p = 0.011) were predictive for LC. Multivariate analysis showed that only extrahepatic disease status
at time of treatment was a significant factor (p = 0.033 and p = 0.009, respectively) for PFI and OS. Acute nausea
or fatigue grade 1 was observed in 24.1 % of the patients and only 1 patient (1.9 %) had a side effect of grade≥ 2.
Conclusions: Robotic real-time motion-compensated SBRT is a safe and effective treatment for one to four liver
metastases. Reducing the PTV prescription dose and keeping a high mean GTV dose allowed the reduction of
toxicity while maintaining a high local control probability for the treated lesions.
Keywords: Liver metastases, Gross tumor volume optimization, Stereotactic body radiation therapy, CyberKnife
robotic radiosurgery
Background
Liver metastases are common for disseminated cancer
disease, especially for primary tumor sites in the
gastrointestinal tract [1, 2]. The liver is even amongst
the first and possibly only site of failure in patients
with colorectal cancer. Synchronous liver metastases
are found in 15–25 % of these patients at the time of
primary diagnosis, and another 20 % of patients will
develop metachronous liver metastases. Hepatic resection
represents the gold standard for local therapy [3, 4],
although only 10–20 % of all patients are candidates for
surgical resection, depending on tumor size, localization, or
liver function [4, 5]. Patients with untreated hepatic metas-
tases have a very poor prognosis with an actuarial 5-year
overall survival (OS) of < 3 % and a mean OS of 4–12
months [6].
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In comparison the 5-year actuarial OS for patients
with resected liver metastases ranges between 32 and
74 % [7–9]. Because of the large amount of inoperable
patients and because hepatic recurrences occur in nearly
two thirds of the patients after surgical resection [10],
several alternative or complementary therapies have
been established such as radiofrequency ablation (RFA)
[11], trans-arterial chemoembolization (TACE) [12],
laser-induced thermotherapy (LITT) [13], selective in-
ternal radiation therapy (SIRT) [14] or stereotactic body
radiation therapy (SBRT) [15–21].
New developments in SBRT technology, such as
active-breathing-controlled tumor localization [21] or
real-time tumor-tracking technology (CyberKnife®,
Accuray Incorporated, Sunnyvale, CA, USA) [22, 23],
have allowed the application of high radiation doses
within the gross tumor volume (GTV) while applying
minimal safety margins aiming at maximal sparing of
surrounding normal tissue. This is especially challenging
in presence of large tumor motion which is predomin-
antly found in the lower part of the lung and in the liver.
Besides, a dose response relationship for local control of
liver metastases has been reported and effective SBRT of
liver metastases should aim at delivering high biologic-
ally effective radiation doses (BED) within the tumor
[15, 17, 24].
Nevertheless, using the small CyberKnife beams, this
task is not always straightforward as compared to stand-
ard isocentric SBRT with gantry-based linear accelera-
tors. Therefore, our approach was to optimize robotic
radiosurgery treatment planning to maximize the dose
within the GTV at the potential cost of planning target
volume (PTV) coverage while adhering to safe normal
tissue constraints. The aim of our retrospective analysis
for local control (LC), progression-free interval (PFI),
overall survival (OS), and toxicity was to validate our
GTV-optimized treatment approach in comparison to
other published studies.
Methods
Patient characteristics
This retrospective analysis was approved by the respect-
ive ethics committees of the treating centers. Between
March 2011 and July 2015, 52 patients with a total of 91
metastatic liver lesions (one to four metastases per
patient) were treated with SBRT using the CyberKnife
real-time tracking system at two centers performing ra-
diosurgery (Table 1). Three patients had two and three
patients had three repeat SBRT procedures for new liver
metastases which developed during follow-up, and were
included in the analysis. All patients’ primary tumors
were controlled at the time of SBRT treatment and
SBRT was chosen as first therapeutic option at initial
diagnosis of liver metastases in 26.9 %, at the diagnosis
of recurrent metastases after local therapy in 9.6 %, or at
the diagnosis of new metastases after systemic failure in
63.5 % of the patients. Furthermore, 63.5 % of the pa-
tients had no extrahepatic disease, while 22.8 % had
stable extrahepatic disease, and 13.7 % underwent simul-
taneous treatment of extrahepatic disease at the time of
SBRT, mostly consisting of lung, bone or lymph node
metastases. All patients were considered oligometastatic
having less than five metastatic sites. Median baseline
Karnofsky Index was 90 % (range, 60–100 %) and me-
dian GTV volume was 12 cc (min 1 cc and max 372 cc).
Fiducial implantation
Prior to treatment either GoldAnchor™ (Naslund Medical
AB, Huddinge, Sweden) or solid gold fiducial markers (IZI
Medical Products, Owings Mills, MD, USA) were
implanted as close to the lesion as possible with computer
tomography (CT) or ultrasound (US) guidance. Depending
on the size, shape and number of the lesions, one (e.g., for a
small spherical lesion) to five (e.g., for multiple lesions)
fiducials were implanted.
Treatment planning
Treatment planning was performed on standard non-
contrast-enhanced CT scans at regular end expiration
breath hold with 1.5-mm slice thickness. The planning
CT was fused with a T2- and multiple T1-weighted mag-
netic resonance images (MRI) at 0–20 min after injec-
tion of intravenous contrast agent (Gadovist, Bayer,
Germany). When MRI was not available (e.g., due to
pacemaker) a secondary contrast-enhanced CT was add-
itionally used for treatment planning. A composite GTV
was defined as the sum of the GTVs contoured on each
of the fused CT or MRI images according to a previously
published CyberKnife protocol [24]. The clinical target
volume (CTV) consisted of the GTV with an expansion
of 5 mm in all directions within the liver (excluding ex-
tension beyond liver parenchyma) to encompass micro-
scopic tumor spread [25]. The PTV included the CTV
and an expansion of 3 mm in all directions to encom-
pass the targeting uncertainties for the CyberKnife
system [26, 27].
Beam optimization was performed using the Multi-
Plan® (Accuray) treatment planning software (version 3.5
and 4.5) and the Sequential Multi-Objective Optimizer
[28] according to the consensus guidelines for treatment
planning for robotic radiosurgery [29]. The main objec-
tives for optimization were to maximize the GTV mean
dose above 3 × 18 Gy (BED10 = 151.2 Gy10), to cover
95 % of the PTV with 3 × 15 Gy with a maximum dose
of 3 × 20 Gy, and to minimize all critical structures ac-
cording to the ALARA (As Low As Reasonably Achiev-
able) principle. If due to critical organ constraints [30]
3 × 15 Gy was not achievable for the PTV, the
Andratschke et al. Radiation Oncology  (2016) 11:74 Page 2 of 10
Table 1 Patient, tumor and treatment characteristics
Total %
Patients 52
Lesions 91
Gender
Male 30 57.7
Female 22 42.3
Age Median (range) in years 62 (37–89)
Karnofsky-Index Median (range) in % 90 (60–100)
Primary Tumor
Colorectal 22 42.3
Breast 4 7.7
Lung 4 7.7
Other 22 42.3
Extra-hepatic Disease
No 33 63.5
Yes 19 36.5
Time of SBRT
At first diagnosis of metastases 14 26.9
After local therapy 5 9.6
After chemotherapy 33 63.5
Time to SBRT Median (range) in months 7 (0–56)
Lesions per Treatment
1 39 63.9
2 17 27.9
3 2 3.3
4 3 4.9
Total
Repeat Procedures
2 3 5.8
3 3 5.8
GTV Volume Median (range) in cc 12 (1–372)
Max GTV Dimension Median (range) in cm 2.8 (1.2–8.9)
PTV Dose per Lesion
3 × 15 Gy 21 23.0
3 × 14 Gy 10 11.0
3 × 13 Gy 15 20.9
3 × 12 Gy 14 15.4
3 × 8-10 Gy 10 11.0
4 × 7-10 Gy 11 12.1
5 × 6-9 Gy 10 11.0
PTV Prescription BED Median (range) in Gy 86.1 (40.6–112.5)
GTV Mean BED Median (range) in Gy 142.1 (60.2–165.3)
GTV Gross Tumor Volume, PTV Planning Target Volume, BED Biological Effective Dose
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prescription dose was lowered (3 × 8–14 Gy) in 34.1 %
of the cases and/or more protracted fractionation sched-
ules were used (4–5 fractions) in 23.1 % of the cases.
The aim in these cases was to maintain a high GTV
mean dose above 3 × 18 Gy (BED10 = 151.2 Gy10) while
not raising the maximum dose of 3 × 20 Gy (BED10 =
180 Gy10). In other words, whenever the PTV prescrip-
tion dose was lowered, we compensated by generating
steeper dose gradients in the CTV/PTV margin zone
outside the GTV (Fig. 1). The final prescribed dose to
the PTV ranged between 23 Gy and 45 Gy (median
39 Gy) to the 60–83 % isodose (median 75 %) and the
mean GTV dose ranged between 33 Gy and 57 Gy (me-
dian 52.5 Gy) resulting in a median BED10 of 86.1 Gy10
(min 40.6 Gy10 and max 112.5 Gy10) surrounding 95 %
of the PTV and of 142.1 Gy10 (min 60.2 Gy10 and max
165.3 Gy10) for the mean GTV.
Treatment delivery
SBRT was delivered using the Synchrony® Respiratory
Tracking System (Accuray) (versions 8.5 and 9.5). All
patients were loosely immobilized using a custom made
vacuum mattress (HEK Medical, Germany) and initially
aligned using the spinal vertebra closest to the lesions.
Respiratory motion was initially modeled, updated dur-
ing treatment, and compensated during beam-on periods
using the prediction of two to three LED chest markers
which were correlated to one to five previously im-
planted gold fiducial markers detected on orthogonal x-
ray imaging [22, 23, 31]. Combined average tracking
Fig. 1 CyberKnife treatment plan of a 226 cc metastasis in the upper liver overlaid on contrast enhanced T1-weighted MRI in axial (upper right),
sagittal (lower left), and coronal (lower right) view. The prescription dose to the planning target volume was lowered to 3 × 12 Gy (BED10 =
79.2 Gy10) to the 60 % isodose due to the size and critical organ constraints (i.e., the heart). The mean gross tumor volume dose was optimized
to 140 Gy10. Twenty-eight months after treatment, the patient was alive and had complete response with no further development of metastases
in the meantime. Upper left: Planning CT with final CyberKnife treatment beams (cyan) from the initially generated beam assortment (blue/red)
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errors (i.e., correlation and predictions errors) were kept
below 1 mm and average rotation errors were minimized
by aligning the patient to the average breathing phase, if
rotation was detectable by the CyberKnife system.
Median fraction treatment time was 41 min (range 18–
76 min), excluding setup time.
Follow-up and statistical analysis
All patients were observed 6 weeks after the end of their
SBRT treatment and every 3 months thereafter. Every
follow-up included the recording of possible adverse
events according to the Common Terminology Criteria
for Adverse Events (CTCAE, Version 4.03) for acute tox-
icity and the Radiation Therapy Oncology Group
(RTOG) and European Organization for Research and
Treatment of Cancer (EORTC) criteria for late toxicity.
Imaging during follow-up was kept similar to the plan-
ning imaging (contrast-enhanced MRI or CT where ap-
plicable) and evaluated using the Response Evaluation
Criteria In Solid Tumors (RECIST) with a dedicated
focus on differentiation of radiation effects in the liver
versus actual tumor growth.
In our statistical analysis, we evaluated local control
(LC), progression-free interval (PFI), overall survival
(OS) and toxicity. Local control was defined as complete
remission (CR), partial remission (PR) or stable tumor
size (ST) and was independently confirmed by PET im-
aging when CT or MRI gave suspicious but inconclusive
results. All time points for LC, PFI and OS were calcu-
lated from the end of SBRT treatment to the respective
event; death of any cause was the endpoint for OS. In
case of multiple SBRT treatments, PFI and OS were cal-
culated from the end of the first SBRT series and for LC
each lesion was observed separately from the end of the
respective SBRT treatment. In case of local recurrence,
time to first description of suspected recurrence (back
dating) was recorded. Surviving patients without a dis-
ease progression were censored at last follow-up. All
curves were estimated using the Kaplan-Meier method.
The comparison of different patient or dosimetry
groups was performed using the log-rank-test for the
univariate and using cox-regression for the multivariate
analysis. For LC histology, GTV volume, PTV prescrip-
tion dose expressed as BED and GTV mean dose
expressed as BED and for PFI and OS gender, age, GTV
volume, cumulative GTV volume, Karnofsky perform-
ance status, histology, previous systemic treatment, ex-
trahepatic tumor status and number of metastases were
used as variables in the univariate analysis. For the indi-
cation of statistical significance a p-value of ≤ 0.05 was
considered. Kaplan-Meier survival estimates and curves
were calculated using the statistical program SPSS
(Version 20.0, IBM, Armonk, USA). Cox regression sur-
vival analysis was performed using the R programming
language for statistical computing (Version 3.2.3, The R
Foundation for Statistical Computing, Vienna, Austria).
Results
At the time of analysis, the median follow-up for all pa-
tients after each SBRT treatment was 17 months (range,
2–49 months). Censoring for 1 year was 37.4 % and for
2 years was 64.8 %.
Local control
Local control (LC) was analyzed per treated lesions
(n = 91). The overall crude LC at time of analysis
was 89.0 %. The 2-year actuarial LC rate for all treated liver
metastases was 82.1 % (Fig. 2). All 10 local failures occurred
in patients with primary colorectal cancer (Fig. 3). Nine out
of the 10 local failures occurred in two patients (one patient
with two treatments of one and four metastases and one
patient with one treatment of four metastases). Two out of
ten local failures were marginal recurrences after previous
SBRT treatment (re-treatment recurrences), and the
remaining eight were from two patients who were treated
for four metastases each and experienced simultaneous in-
field recurrences. Five recurrences were re-treated with
SBRT (two patients with one and four treated metastases),
one recurrence was resected and four recurrences (one pa-
tient with four treated metastases) were treated with further
chemotherapy only. In univariate analysis histology (colo-
rectal cancer vs. other primary cancers, p < 0.001), PTV
prescription BED10 (Hazard Ratio HR 0.95, 95 % CI 0.91–
0.98, p = 0.002) and GTV mean BED10 (HR 0.975, CI
0.954–0.996, p = 0.011), both variables considered as
continuous variables, were predictive for local control.
Interestingly, all local recurrences occurred in colorec-
tal metastases (Table 2). The 2-year actuarial LC rate
for PTV prescription BED10 > 86.1 Gy10 was 96.6 %
and for ≤ 86.1 Gy10 68.1 % (Fig. 3), the difference being
significant (p = 0.005). In multivariate analysis PTV
prescription BED10 seemed to be the dominating factor for
LC, though not reaching significance (p = 0.069). However,
the results of the multivariate analysis should be interpreted
with caution due to the limited number of events (n = 10)
and all events occurring in colorectal cancer patients har-
boring the risk of over fitting.
Progression-free interval
Progression-free interval (PFI) analysis was based on
treated patients (n = 52). Twenty-eight patients (53.8 %)
developed new intrahepatic metastases. Eight of these
patients were re-treated locally (six with SBRT). Twenty-
four patients (46.2 %) developed extrahepatic metastases,
three of whom were treated locally (all with SBRT).
The median progression-free interval was 9 months
(range, 1–36 months) and the 1- and 2-year actuarial
progression-free interval rates were 35.1 and 17.7 %,
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respectively (Fig. 2). In univariate analysis patient age at
time of SBRT, gender, tumor histology, number of treated
metastases per patient, and GTV volume (largest metasta-
ses or cumulative volume) were not predictive for PFI
(Table 2). On the other hand, status of extrahepatic disease
at time of SBRT (HR 3.05, CI 1.59–5.84, p < 0.001),
Karnofsky Index (HR 0.51, CI 0.27–0.98, p = 0.041), and
prior liver therapy (HR 2.10, CI 1.04–4.23, p = 0.034) had
significant effects on the PFI in our analysis. Multivariate
analysis showed only the status of extra-hepatic disease at
time of SBRT to be a significant factor for PFI (HR 2.33, CI
1.07–5.07, p = 0.033).
Fig. 2 Left: Kaplan-Meier estimates for local control progression-free interval and overall survival. Right: Overall survival stratified by extrahepatic
disease status, SD = stable disease, PD = progressive disease, NED = no evidence of disease
Fig. 3 Left: Kaplan-Meier estimates for local control stratified by primary tumor site. Right: Kaplan-Meier estimates for local control stratified by
planning target volume biologically effective prescription dose
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Overall survival
Overall survival (OS) analysis was based on treated patients
(n = 52). Median overall survival at time of analysis was
23 months and cause of death was further tumor progres-
sion in 91.2 %. Actuarial 1- and 2-year overall survival rates
were 70.2 and 45.0 %, respectively (Fig. 2). In univariate
analysis patient age at time of SBRT, gender, Karnofsky-
Index, number of treated metastases, prior liver therapy
and GTV volume (largest metastases or cumulative vol-
ume) were not predictive for OS (Table 2). The 2-year actu-
arial OS was better for patients with colorectal cancer as
the primary tumor site (58.7 %) compared to other primary
tumor sites (35.7 %), although the difference was not statis-
tically significant (p = 0.364). The only statistically signifi-
cant variable prognostic for OS on univariate (HR 2.64, CI
1.30–5.38, p = 0.005) and multivariate (HR 2.59, CI 1.26–
5.32, p = 0.009) analyses was the status of extrahepatic
disease (no evidence of disease vs. stable or progressive ex-
trahepatic disease) at time of SBRT (Fig. 2).
Toxicity
One patient developed an infected encapsulated
hematoma in the liver and a right-sided pleural effusion
after fiducial implantation. Overall, radiation treatment
itself was well tolerated. Grade 1 acute nausea or fatigue
were observed in 24.1 % of the patients and nausea was
generally handled with antiemetic. Only one patient
(1.9 %) had a grade ≥ 2 side effect and required a stent
implantation for hepatic vein occlusion after SBRT of a
tumor attached to that vein.
Table 2 Univariate and multivariate analysis for local control, progression free interval and overall survival according to patient and
tumor characteristics
Univariate Analysis Multivariate Analysis
HR (CI) p-value HR (CI) p-value
Local control
Prior Therapy 1.38 (0.36–5.33) 0.642
Histology a <0.001 (0-Inf) < 0.001 < 0.001 (0-Inf) 0.998
GTV Volume b 0.96 (0.90–1.02) 0.163
PTV Prescription BED b 0.95 (0.92–0.98) 0.002 0.961 (0.921–1.003) 0.069
GTV Mean BED b 0.975 (0.954–0.996) 0.011 0.995 (0.973–1.017) 0.664
Progression Free Interval
Karnofsky Index d 0.51 (0.27–0.98) 0.041 0.81 (0.38–1.73) 0.588
Gender 0.79 (0.43–1.46) 0.459 n/a n/a
Age 0.79 (0.43–1.44) 0.435 n/a n/a
Histology a 1.20 (0.65–2.21) 0.564 n/a n/a
Prior Therapy 2.10 (1.04–4.23) 0.034 1.57 (0.73–3.37) 0.244
Extra-hepatic Disease Status c 3.05 (1.59–5.84) 0.000 2.33 (1.07–5.07) 0.033
Largest GTV Volume b 1.002 (0.998–1.006) 0.283 n/a n/a
Cumulative GTV Volume b 1.003 (0.999–1.007) 0.110 n/a n/a
Number of Treated Metastases 1.77 (0.92–3.41) 0.082 1.19 (0.84–1.76) 0.386
Overall Survival
Karnofsky Index d 0.78 (0.37–1.62) 0.496 n/a n/a
Gender 0.64 (0.31–1.29) 0.204 n/a n/a
Age 0.78 (0.38–1.58) 0.483 n/a n/a
Histology a 0.74 (0.37–1.48) 0.396 n/a n/a
Prior Therapy 1.86 (0.83–4.17) 0.124 n/a n/a
Extra-hepatic Disease Status c 2.64 (1.30–5.38) 0.005 2.59 (1.26–5.32) 0.009
Largest GTV Volume b 1.003 (0.998–1.008) 0.227 n/a n/a
Cumulative GTV Volume b 1.004 (0.999–1.009) 0.067 1.004 (0.999–1.009) 0.096
Number of Treated Metastases 1.29 (0.62–2.67) 0.495 n/a n/a
GTV Gross Tumor Volume, PTV Planning Target Volume, BED Biological Effective Dose, HR hazard ratio, CI 95 % confidence interval
a Colorectal Cancer vs. Other Primary Cancer
b Evaluated as Continuous Variables
c No Evidence of Diseases vs. Stable or Progressive Extra-hepatic Diseases
d ≤ 80 % vs. 90–100 %
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Discussion
Currently, there is no consensus on how to prescribe the
dose and optimize the dose distribution within the gross
tumor volume (GTV) or even the planning target vol-
ume (PTV) for SBRT treatments. Current Radiation
Therapy Oncology Group (RTOG) clinical trial protocols
even allow for a considerable inhomogeneity of dose
within the PTV, as long as the PTV prescription dose is
maintained. Specifically, the PTV-encompassing isodose
line in some protocols may range from 60–90 %, giving
rise to a possible dose maximum difference of almost
50 % within the same patient cohort. With the focus on
the PTV-encompassing isodose line in such approaches,
considerable differences in dose distribution in different
GTVs may even occur within the same patient! This be-
comes especially problematic with intensity modulation
or in the case of CyberKnife with small non-isocentric
non-coplanar beam arrangements. Therefore, it is cur-
rently impossible to compare reported dose prescription
in the literature, as inhomogeneity is generally not expli-
citly reported.
The treatment planning approach in our institutions
has been to prescribe the dose to the PTV as well, but
additionally to optimize the dose distribution in order to
achieve a concentric dose build-up and a high-dose plat-
eau to maximize the dose within the GTV. The present
analysis was designed to evaluate the efficacy and safety
of our GTV-mean-dose optimized treatment planning
method for liver metastases where we allowed the reduc-
tion of the PTV encompassing prescription dose to ad-
here to safe normal tissue constraints using the robotic
CyberKnife system. Due to the small CyberKnife beams,
a ring-like dose distribution with cold spots in the mid-
dle can arise when the center of the PTV is not explicitly
optimized [24, 32]. This is especially true for lesions with
larger GTV-PTV margins such as liver metastases
(8 mm in our case) and when inhomogeneous dose pre-
scriptions are used as is typically the case in SBRT
treatments.
Our local control rates are well in line with previous
publications [15–21, 24, 32–36]. In agreement with
other studies [24, 33–35], we found that the PTV pre-
scription BED10 was a significant factor for local control.
Additionally, we also found a significant influence of
mean GTV BED10 on local control (Table 2), which has
not been demonstrated before. The 2-year actuarial local
control was 100 % for PTV > 100.0 Gy10 vs. 71.5 % for
PTV ≤ 100.0 Gy10 (p = 0.009) and 96.6 % for PTV >
86.1 Gy10 vs. 68.1 % for PTV ≤ 86.1 Gy10 (p = 0.005).
Lanciano et al. [33] and Dewas et al. [34] have reported
both substantially lower 2-year local control rates even
for doses above 100.0 Gy10 and Chang et al. [35] re-
ported the need for 116.5–142.1 Gy10 PTV dose to
achieve > 90 % local control in similar patient cohorts to
ours. On the other hand, our results match those from
Stintzing et al. [36] in which they used a PTV prescrip-
tion dose of 81.6–93.6 Gy10, yet for smaller lesions as
compared to ours. Unfortunately, most published studies
for CyberKnife liver SBRT [24, 32–36] only report the
PTV prescription dose and no details on the dose distri-
bution within the PTV or GTV, therefore, a direct com-
parison to our data is difficult. Although the existence of
strong dose-response relationship has been consistently
reported, a clear conclusion on the minimally required
PTV prescription dose to achieve a certain level of local
control remains unknown. Distinct description and
reporting of the dose distribution and benchmark trials
[29, 37] are necessary for multi-institutional multi-
technology comparison or pooled evaluation of SBRT for
liver metastases.
Also in agreement with other publications [24, 36], we
found significantly better local control for liver metasta-
ses originating from non-colorectal cancer (CRC), as all
local recurrences in our patient cohort occurred only in
CRC patients. In total, three patients with overall ten
liver metastases developed local recurrences within the
first year after SBRT. However, larger patient numbers
are needed to reliably model tumor control probability
with regard to histology. Still, as far as CRC liver metas-
tases are concerned, it remains speculative whether the
observed inferior local tumor control is due to a differ-
ing radio sensibility or due to the observed difference in
PTV prescription BED10. While the mean GTV BED10
was comparable between CRC on non-CRC metastases,
the median PTV prescription BED10 differed signifi-
cantly between the two groups (75 Gy10 vs. 90 Gy10, re-
spectively). Nevertheless, local control for CRC
metastases would only reach 80 % even for PTV pre-
scription BED10 > 90 Gy10, thus a possible effect of dif-
ferent radio sensitivity cannot be excluded. Interestingly,
a recent pooled analysis of SBRT for lung metastases did
not find a dose-dependent difference in local tumor con-
trol for CRC and non-CRC histology [38]. On the other
hand, Ahmed et al. have reported on different radiation
sensibility of CRC metastases depending on anatomical
location, e.g. lung versus liver [39]. Taking other pub-
lished results and ours into account, dose escalation be-
yond a prescription PTV BED10 greater than 112.5 Gy10
(corresponding to 3 × 15 Gy) and a mean GTV BED10
greater than 151.2 Gy10 (corresponding to 3 × 18 Gy) for
non-CRC metastases does not seem necessary.
GTV volume (either based on largest metastases or
on cumulative volume) was not a significant factor for
local control in our patient cohort. The literature
however is controversial regarding tumor size being a
factor for local control after SBRT as some studies
found this to be significant [34, 40] while others did
not [17, 19, 36]. A speculation about the treatment
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planning technique as being one reason for the signifi-
cant or non-significant influence of GTV volume on
local control is beyond the scope of this paper. Still,
we hypothesize under the assumption of the existence
of a GTV dose-volume effect that the high mean GTV
BED10 may have annihilated this effect. Furthermore,
we hypothesize based on our results that an
optimization with reduced PTV prescription dose (if
necessary for adherence to normal tissue constraints)
will not result in significant inferior local control if a
minimum PTV encompassing BED10 of greater
86.1 Gy10 and a high GTV mean BED10 of greater
151.2 Gy10 is maintained.
Overall survival of 45.0 % at 2 years was comparable
to published literature [16–20, 32–36] and comparable
to other local therapy modalities [11–14, 41, 42]. In
our cohort, patients with CRC had better overall sur-
vival at 2 years after SBRT compared to those with
other primary tumors (58.7 vs. 35.7 %), although the
result was not statistically significant. Andratschke et
al. [17] and Rusthoven et al. [43] have reported a sig-
nificant influence of CRC histology on the overall sur-
vival while Dewas et al. [23] and Rule et al. [44] did
not find that overall survival was dependent on pri-
mary tumor site. On the other hand, in our analysis
the status of extra-hepatic disease at time of SBRT was
the most influencing factor on overall survival in
agreement with other studies [17, 35]. Patients with
no evidence of extrahepatic disease had significantly
better overall survival and progression-free intervals.
In our study, acute toxicities were minimal and con-
sisted of grade 1 fatigue, nausea and vomiting in
24.1 % of the patients. Only 1 patient (1.9 %) had a
late toxicity of grade ≥ 2 requiring a stent implantation
after hepatic vein occlusion. Our toxicity data com-
pare favorably well with published reports as they
range at the lower spectrum of reported side effects
[15–20, 32–36].
Limitations to our findings are inherent to the retro-
spective nature of our study, even though we treated
them according to study-like institutional guidelines. Al-
though, a larger number of metastases were evaluated,
the combined analysis of different tumor histologies with
various prior treatments makes thorough determination
of predictive factors difficult. Furthermore, with the low
number of events, especially for local control (n = 10),
serious conclusions from the multivariate analysis can-
not be drawn. Larger patient cohorts, either collected as
a multi-institutional registry or ideally enrolled in a pro-
spective study with coherent patient criteria, longer
follow-up periods and detailed patient and dosimetry in-
formation are needed in order to validate our assump-
tions and to define the patient groups significantly to
benefit from SBRT.
Conclusions
Overall, robotic real-time-motion-compensated SBRT can
be an effective and safe treatment with minimal toxicities
and high local tumor control rates. As long as GTV mean
BED10 greater 151.2 Gy10 is maintained, a significantly
lower PTV prescription BED10 compared to common pub-
lished literature can be sufficient for very high local control
rates. Nevertheless, it seems that even with GTV mean
dose optimization, a reasonable minimum PTV prescrip-
tion BED10 of greater than 86.1 Gy10 is required. Further
analyses of optimal treatment planning, dose schedules and
delivery technique for liver SBRT is required. In the end,
extra-hepatic disease status remains the major independent
factor for overall survival and may guide the decision for in-
tensive local treatment in this patient cohort.
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